ImmunologyCancersPeer-reviewed
The defined TLR3 agonist, Nexavant, exhibits anti-cancer efficacy and potentiates anti-PD-1 antibody therapy by enhancing immune cell infiltration.
Seung‐Hwan Lee, Young-Ho Choi, Soon Myung Kang…·Dong-Ho Kim
This paper evaluates Nexavant, a TLR3 agonist, showing enhanced anti-cancer effects and synergy with anti-PD-1 therapy through immune cell infiltration.
10 citations